Dosing Begins for Next Phase of Trial for Investigational Therapy AL001

Alzamend Neuro has dosed the first patient in the multiple ascending dose portion of its Phase 2a clinical trial of AL001, an investigational oral therapy for dementia related to Alzheimer’s disease. This multiple ascending dose (MAD) part follows positive results from a Phase 1 trial. Topline data from the Phase 2a trial is expected in December. “Advancing AL001 into a Phase IIA clinical trial as planned marks an important milestone for Alzamend,” Stephan Jackman, CEO…

You must be logged in to read/download the full post.